论文部分内容阅读
２０多例肺癌患者手术后服用核糖核酸（ＲＮＡ）制剂，经３年的临床跟踪观察证实：服用ＲＮＡ制剂病人的白细胞（ＷＢＣ）计数，血沉（ＥＳＲ），免疫球蛋白（ＩｇＧ、ＩｇＡ、ＩｇＭ），淋巴细胞亚群Ｔ４Ｔ８和超氧歧化酶（ＳＯＤ）诸项指标的稳定率为１００％。患者的１年生存率为１００％；２年生存率为９５％；３年生存率为７５％，而术后未服用ＲＮＡ制剂而采用化疗的２０例对照组的１年生存率为８０％；２年生存率为５０％；３年生存率为３５％，两组生存率对应比较有显着性差异。此外患者在服用ＲＮＡ制剂后，自觉症状：精神、食欲、睡眠普遍得到改善。观察期间未发现毒副作用。对ＲＮＡ制剂口服抗癌防癌和增强机体免疫功能的机理进行了探讨。
More than 20 patients with lung cancer were treated with ribonucleic acid (RNA) after surgery. After 3 years of clinical follow-up observations, WBC counts, ESR, and immunoglobulins (IgG, IgA, IgM) were recorded in patients taking RNA preparations. The stability of lymphocyte subsets T4T8 and superoxide dismutase (SOD) indicators was 100%. The 1-year survival rate was 100% in patients; the 2-year survival rate was 95%; the 3-year survival rate was 75%; and the 1-year survival rate of 20 control groups who did not take RNA preparations and used chemotherapy was 80%. The 2-year survival rate was 50%; the 3-year survival rate was 35%. There was a significant difference in survival rates between the two groups. In addition, after taking RNA preparations, the patient’s subjective symptoms: mental, appetite, and sleep generally improved. No toxic side effects were observed during the observation period. The mechanism of oral administration of anti-cancer, anti-cancer, and immune function to RNA was discussed.